DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’s Neuroscience Investor Conference on Thursday, April 29th at 11:30am ET. DiaMedica will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.

The recorded presentation will be available on the Investors section of the Company’s website at https://www.diamedica.com/investors/events-presentations beginning Thursday, April 29th.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, visit www.diamedica.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.33
-5.86 (-2.40%)
AAPL  292.96
+2.41 (0.83%)
AMD  452.46
-23.05 (-4.85%)
BAC  54.80
+0.38 (0.69%)
GOOG  354.21
-8.08 (-2.23%)
META  572.82
-11.77 (-2.01%)
MSFT  400.21
-3.20 (-0.79%)
NVDA  201.13
-7.06 (-3.39%)
ORCL  204.02
-1.79 (-0.87%)
TSLA  381.75
-14.94 (-3.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.